145 related articles for article (PubMed ID: 25565435)
1. The aptamer-siRNA conjugates: reprogramming T cells for cancer therapy.
Sakib Hossain DM; Duttagupta P; Kortylewski M
Ther Deliv; 2015 Jan; 6(1):1-4. PubMed ID: 25565435
[No Abstract] [Full Text] [Related]
2. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.
Herrmann A; Priceman SJ; Swiderski P; Kujawski M; Xin H; Cherryholmes GA; Zhang W; Zhang C; Lahtz C; Kowolik C; Forman SJ; Kortylewski M; Yu H
J Clin Invest; 2014 Jul; 124(7):2977-87. PubMed ID: 24892807
[TBL] [Abstract][Full Text] [Related]
3. [Advance in the study of targeting delivery system for siRNA mediated by aptamers].
Wang XL; Wang QQ; Song HF
Yao Xue Xue Bao; 2012 Jul; 47(7):850-5. PubMed ID: 22993847
[TBL] [Abstract][Full Text] [Related]
4. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
Li X; Zhao Q; Qiu L
J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
[TBL] [Abstract][Full Text] [Related]
5. Therapy. Aptamer-lipid nanoparticle conjugates for RNAi in bone.
Sargent J
Nat Rev Endocrinol; 2015 Apr; 11(4):194. PubMed ID: 25707781
[No Abstract] [Full Text] [Related]
6. Reducing Toxicity of Immune Therapy Using Aptamer-Targeted Drug Delivery.
Gilboa E; Berezhnoy A; Schrand B
Cancer Immunol Res; 2015 Nov; 3(11):1195-200. PubMed ID: 26541880
[TBL] [Abstract][Full Text] [Related]
7. Intracellular delivery of RNA-based therapeutics using aptamers.
Thiel KW; Giangrande PH
Ther Deliv; 2010 Dec; 1(6):849-61. PubMed ID: 21643487
[TBL] [Abstract][Full Text] [Related]
8. Ctla-4 blockade plus adoptive T-cell transfer promotes optimal melanoma immunity in mice.
Mahvi DA; Meyers JV; Tatar AJ; Contreras A; Suresh M; Leverson GE; Sen S; Cho CS
J Immunother; 2015; 38(2):54-61. PubMed ID: 25658614
[TBL] [Abstract][Full Text] [Related]
9. Multivalent comb-type aptamer-siRNA conjugates for efficient and selective intracellular delivery.
Yoo H; Jung H; Kim SA; Mok H
Chem Commun (Camb); 2014 Jun; 50(51):6765-7. PubMed ID: 24830507
[TBL] [Abstract][Full Text] [Related]
10. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity.
Zhou J; Satheesan S; Li H; Weinberg MS; Morris KV; Burnett JC; Rossi JJ
Chem Biol; 2015 Mar; 22(3):379-90. PubMed ID: 25754473
[TBL] [Abstract][Full Text] [Related]
11. Aptamer mediated siRNA delivery.
Chu TC; Twu KY; Ellington AD; Levy M
Nucleic Acids Res; 2006 Jun; 34(10):e73. PubMed ID: 16740739
[TBL] [Abstract][Full Text] [Related]
12. Therapy. Targeted delivery of packaged siRNA promotes osteogenesis.
Duarte JH
Nat Rev Rheumatol; 2015 Apr; 11(4):196. PubMed ID: 25708498
[No Abstract] [Full Text] [Related]
13. Enhancing siRNA effects in T cells for adoptive immunotherapy.
Morris K; Castanotto D; Al-Kadhimi Z; Jensen M; Rossi J; Cooper LJ
Hematology; 2005 Dec; 10(6):461-7. PubMed ID: 16321811
[TBL] [Abstract][Full Text] [Related]
14. Nucleic acid nanotechnology for cancer treatment.
Jin JO; Kim G; Hwang J; Han KH; Kwak M; Lee PCW
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188377. PubMed ID: 32418899
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.
Condomines M; Arnason J; Benjamin R; Gunset G; Plotkin J; Sadelain M
PLoS One; 2015; 10(6):e0130518. PubMed ID: 26110267
[TBL] [Abstract][Full Text] [Related]
16. The application of aptamers in cancer research: an up-to-date review.
Hu M; Zhang K
Future Oncol; 2013 Mar; 9(3):369-76. PubMed ID: 23469972
[TBL] [Abstract][Full Text] [Related]
17. Circular Bispecific Aptamer-Mediated Artificial Intercellular Recognition for Targeted T Cell Immunotherapy.
Yang Y; Sun X; Xu J; Cui C; Safari Yazd H; Pan X; Zhu Y; Chen X; Li X; Li J; Tan W
ACS Nano; 2020 Aug; 14(8):9562-9571. PubMed ID: 32584540
[TBL] [Abstract][Full Text] [Related]
18. [Cancer immunotherapy by immuno-checkpoint blockade].
Kawakami Y
Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
[TBL] [Abstract][Full Text] [Related]
19. Whole tumor cell vaccines for glioma immunotherapy.
Field CS; Hermans IF; Hunn MK
Immunotherapy; 2016; 8(4):387-9. PubMed ID: 26973119
[No Abstract] [Full Text] [Related]
20. Cancer Immunotherapy Researchers Focus on Refining Checkpoint Blockade Therapies.
Jacob JA
JAMA; 2015 Nov; 314(20):2117-9. PubMed ID: 26599172
[No Abstract] [Full Text] [Related]
[Next] [New Search]
